Receipt of Research & Development Tax Incentive
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Avecho Biotechnology Limited has announced the receipt of funds under the Australian Government’s Research and Development Tax Incentive Scheme, confirming a significant financial boost for the company. The funds will be utilized to repay advances made by Endpoint Capital and to support ongoing operations and commercialization efforts. This announcement highlights Avecho's commitment to developing cannabinoid formulations for pharmaceutical registration, particularly for insomnia treatment.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Avecho Biotechnology Limited on 6ix
In the deck
Earlier from Avecho Biotechnology
- Avecho completes treatment for Phase III interim analysis
- Expiry of Listed Options
- March 2026 Quarterly Activities Report & Appendix 4C
- Avecho completes recruitment for Phase III interim analysis
- Annual Report 31 December 2025
Later from Avecho Biotechnology
- Positive interim results from Phase III insomnia program
- Positive interim analysis advances Avecho Phase III insomnia program
- June 2026 Quarterly Activities Report & Appendix 4C
- Japanese patent granted for CBD capsule
- Small Holding Share Sale Facility Completion
Follow Avecho Biotechnology into a list and get an email when it puts out news.
Follow Avecho Biotechnology